



UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 31 2011

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

This letter clarifies the communication of March 29, 2011 regarding application for patent term extension of U.S. Patent No. RE38,115 under 35 U.S.C. § 156. That letter incorrectly identified on the top of page 2,

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Since it appears to the USPTO that each of the active ingredients in NUEDEXTA has been previously approved by FDA as described in the March 29, 2011 letter, the patent does not appear to be eligible for extension because the permission for the commercial marketing or use of NUEDEXTA fails to meet the requirements of §156(a)(5)(A).

Thus, our review of the application to date indicates that the subject patent would NOT be eligible for extension of the patent term under 35 U.S.C. § 156.

Furthermore, no determination has been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, as such, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till
Mary C. Till
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Kevin G. Shaw
Hogan Lovells US LLP
555 Thirteenth St., NW
Washington, DC 20004